# A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma

> **NCT00872521** · PHASE2 · COMPLETED · sponsor: **Janssen-Cilag Pty Ltd** · enrollment: 107 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** PAD induction

## Key facts

- **NCT ID:** NCT00872521
- **Lead sponsor:** Janssen-Cilag Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-03
- **Final completion:** 2011-11
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00872521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00872521, "A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00872521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*